{
    "data": [
        {
            "id": "69a028b624c37e0001bb30ca",
            "title": "Primo Brands Q4 Earnings Summary &amp; Key Takeaways",
            "description": "<div><div class=\"sc-gfrmXj kPLDLR\"><!--$--><p class=\"block core-block\">The earnings results for <strong>Primo Brands</strong> (NYSE:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/PRMB\" target=\"_blank\">PRMB</a>) for Q4 were made public on Thursday, February 26, 2026 at 06:00 AM.</p><!--/$--><!--$--><p class=\"block core-block\">Here's a comprehensive overview of the announcement.</p><!--/$--><!--$--><h3 class=\"block core-block\">Earnings</h3><!--/$--><!--$--><p class=\"block core-block\">Primo Brands beat estimated earnings by 30.0%, reporting an EPS of $0.26 versus an estimate of $0.2.</p><!--/$--><!--$--><p class=\"block core-block\">Revenue was up $157.10 million from the same period last year.</p><!--/$--><!--$--><h3 class=\"block core-block\">Earnings History Overview</h3><!--/$--><!--$--><p class=\"block core-block\">Last quarter the company beat on EPS by $0.05 which was followed by a 18.31% drop in the share price the next day.</p><!--/$--><!--$--><p class=\"block core-block\">Here's a look at Primo Brands's past performance:</p><!--/$--><!--$?--><template id=\"B:2\"></template><div></div><!--/$--><!--$--><p class=\"block core-block\">To track all earnings releases for Primo Brands <a href=\"https://www.benzinga.com/quote/PRMB/earnings\" target=\"_blank\">visit their earnings calendar here.</a> </p><!--/$--><!--$--><p class=\"block core-block\">This article was generated by Benzinga's automated content engine and reviewed by an editor.</p><!--/$--></div></div>",
            "image": "https://www.benzinga.com/files/images/story/2025/11/06/analyst_ratings_8.jpg",
            "link": "https://www.benzinga.com/insights/earnings/26/02/50879545/primo-brands-q4-earnings-summary-key-takeaways",
            "pub_date": "2026-02-26 19:04:25",
            "source": "benzinga",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "69a028bb24c37e0001bb30d3",
            "title": "Privia Health Gr Earnings Report: Q4 Overview",
            "description": "<div><div class=\"sc-gfrmXj kPLDLR\"><!--$--><p class=\"block core-block\">The Q4 earnings report for <strong>Privia Health Gr</strong> (NASDAQ:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/PRVA\" target=\"_blank\">PRVA</a>) was released on Thursday, February 26, 2026 at 06:00 AM.</p><!--/$--><!--$--><p class=\"block core-block\">Here's what investors need to know about the latest announcement.</p><!--/$--><!--$--><h3 class=\"block core-block\">Earnings</h3><!--/$--><!--$--><p class=\"block core-block\">Privia Health Gr beat estimated earnings by 92.31%, reporting an EPS of $0.25 versus an estimate of $0.13.</p><!--/$--><!--$--><p class=\"block core-block\">Revenue was up $80.30 million from the same period last year.</p><!--/$--><!--$--><h3 class=\"block core-block\">Past Earnings Performance</h3><!--/$--><!--$--><p class=\"block core-block\">Last quarter the company beat on EPS by $0.14 which was followed by a 2.29% drop in the share price the next day.</p><!--/$--><!--$--><p class=\"block core-block\">Here's a look at Privia Health Gr's past performance:</p><!--/$--><!--$?--><template id=\"B:2\"></template><div></div><!--/$--><!--$--><p class=\"block core-block\">To track all earnings releases for Privia Health Gr <a href=\"https://www.benzinga.com/quote/PRVA/earnings\" target=\"_blank\">visit their earnings calendar here.</a> </p><!--/$--><!--$--><p class=\"block core-block\">This article was generated by Benzinga's automated content engine and reviewed by an editor.</p><!--/$--></div></div>",
            "image": "https://www.benzinga.com/files/images/story/2025/11/06/analyst_ratings_3.jpg",
            "link": "https://www.benzinga.com/insights/earnings/26/02/50879554/privia-health-gr-earnings-report-q4-overview",
            "pub_date": "2026-02-26 19:04:30",
            "source": "benzinga",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "69a025f724c37e0001bb2eca",
            "title": "Sarepta CEO To Jump Ship After &#39;Tumultuous&#39; Year",
            "description": "<div><div class=\"sc-gfrmXj kPLDLR\"><!--$?--><template id=\"B:2\"></template><div></div><!--/$--><!--$?--><template id=\"B:3\"></template><div></div><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><h2 class=\"wp-block-heading\">Earnings Snapshot</h2><!--/$--><!--$--><p class=\"block core-block\">On Wednesday, Sarepta Therapeutics reported an adjusted loss of $3.58 per share, missing the Wall Street estimate loss of $1.31. Sales reached $442.93 million, beating the <a href=\"https://www.benzinga.com/calendars/earnings\" rel=\"noreferrer noopener\" target=\"_blank\">consensus of $391.92 million</a>.</p><!--/$--><!--$--><p class=\"block core-block\">The sales fell 33% year over year, primarily reflecting $273.8 million less in net product revenue of Elevidys as a result of lower volume following the company’s decision to suspend shipments of Elevidys to non-ambulatory patients in the U.S. in June 2025.</p><!--/$--><!--$--><div class=\"sc-jHrKIi gTZsSs\"></div><!--/$--><!--$?--><template id=\"B:4\"></template><div></div><!--/$--><!--$--><h2 class=\"wp-block-heading\">Management Transition</h2><!--/$--><!--$--><p class=\"block core-block\">In an SEC filing on Wednesday, Douglas Ingram <a href=\"https://www.benzinga.com/secfilings/26/02/50873570/sarepta-therapeutics-inc-general-corporate-statement-form8-0001193125-26-072064\" rel=\"noreferrer noopener\" target=\"_blank\">shared</a> his plan to retire as Chief Executive Officer by the end of 2026 or upon the appointment of his replacement. The company has commenced a search.</p><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><h2 class=\"wp-block-heading\">Analyst View</h2><!--/$--><!--$?--><template id=\"B:5\"></template><div></div><!--/$--><!--$--><p class=\"block core-block\">Although the company has guided for stable PMO revenue in 2026, given the <a href=\"https://www.benzinga.com/trading-ideas/movers/25/11/48608201/sarepta-therapeutics-stock-is-tumbling-after-the-close-heres-why\" rel=\"noreferrer noopener\" target=\"_blank\">recent failure</a> of the ESSENCE trial, analyst <strong>Sami Corwin </strong>is hesitant due to concerns that Vyondys 53 and Amondys 45 may lose their marketing authorization.</p><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$?--><template id=\"B:6\"></template><div></div><!--/$--><!--$--><p class=\"block core-block\">Last, while investors have polarized views of CEO Doug Ingram, uncertainty about his successor could cause additional stock volatility in the near term. Taken together, William Blair views the stock’s near-term upside potential as limited and reiterates its <a href=\"https://www.benzinga.com/quote/SRPT/analyst-ratings\" rel=\"noreferrer noopener\" target=\"_blank\">rating of Market Perform</a>.</p><!--/$--><!--$--><h2 class=\"wp-block-heading\">Technical Analysis</h2><!--/$--><!--$--><p class=\"block core-block\">Currently, the stock is trading 3.5% below its 20-day simple moving average (SMA) and 9.8% below its 100-day SMA, indicating a bearish trend in the short to medium term. Over the past 12 months, shares have decreased significantly and are currently positioned closer to their 52-week lows than highs.</p><!--/$--><!--$--><div class=\"nativo-placement-in-content-ap\"></div><!--/$--><!--$--><p class=\"block core-block\">The RSI is at 50.00, which is considered neutral territory, suggesting that the stock is neither overbought nor oversold. Meanwhile, MACD is at -0.10, below its signal line at -0.05, indicating bearish pressure on the stock.</p><!--/$--><!--$--><p class=\"block core-block\">The combination of neutral RSI and bearish MACD suggests mixed momentum, indicating that traders should watch for potential shifts in market sentiment.</p><!--/$--><!--$--><ul class=\"wp-block-list\">\n<li><strong>Key Resistance</strong>: $20.00</li>\n<li><strong>Key Support</strong>: $15.00</li>\n</ul><!--/$--><!--$--><p class=\"block core-block\"><strong>SRPT Price Action:</strong> Sarepta Therapeutics shares were down 3.53% at $18.30 during premarket trading on Thursday, according to <a href=\"https://pro.benzinga.com/dashboard\" rel=\"noreferrer noopener\" target=\"_blank\">Benzinga Pro data</a>.</p><!--/$--><!--$--><p class=\"block core-block\"><em>Photo via Shutterstock</em></p><!--/$--><!--$--><div class=\"bz-optimizely-campaign bz-optimizely-campaign-bottom-50879034\" data-nosnippet=\"true\"></div><!--/$--></div></div>",
            "image": "https://www.benzinga.com/files/images/story/2026/02/26/Sarepta-Therapeutics.jpeg",
            "link": "https://www.benzinga.com/markets/earnings/26/02/50879034/sarepta-ceo-to-jump-ship-after-tumultuous-year",
            "pub_date": "2026-02-26 18:52:43",
            "source": "benzinga",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "69a020ab24c37e0001bb2e75",
            "title": "Canadian Imperial Bank Earnings Review: Q1 Summary",
            "description": "<div><div class=\"sc-gfrmXj kPLDLR\"><!--$--><p class=\"block core-block\"><strong>Canadian Imperial Bank</strong> (NYSE:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/CM\" target=\"_blank\">CM</a>) reported its Q1 earnings results on Thursday, February 26, 2026 at 05:30 AM.</p><!--/$--><!--$--><p class=\"block core-block\">Here's what investors need to know about the announcement.</p><!--/$--><!--$--><h3 class=\"block core-block\">Earnings</h3><!--/$--><!--$--><p class=\"block core-block\">Canadian Imperial Bank beat estimated earnings by 13.79%, reporting an EPS of $1.98 versus an estimate of $1.74.</p><!--/$--><!--$--><p class=\"block core-block\">Revenue was up $897.00 million from the same period last year.</p><!--/$--><!--$--><h3 class=\"block core-block\">Overview of Past Earnings</h3><!--/$--><!--$--><p class=\"block core-block\">In the previous quarter, the company beat on EPS by $0.11, resulting in a 0.64% increase change in the share price the following day.</p><!--/$--><!--$--><p class=\"block core-block\">Here's a look at Canadian Imperial Bank's past performance:</p><!--/$--><!--$?--><template id=\"B:2\"></template><div></div><!--/$--><!--$--><p class=\"block core-block\">To track all earnings releases for Canadian Imperial Bank <a href=\"https://www.benzinga.com/quote/CM/earnings\" target=\"_blank\">visit their earnings calendar here.</a> </p><!--/$--><!--$--><p class=\"block core-block\">This article was generated by Benzinga's automated content engine and reviewed by an editor.</p><!--/$--></div></div>",
            "image": "https://www.benzinga.com/files/images/story/2025/11/06/analyst_ratings_5.jpg",
            "link": "https://www.benzinga.com/insights/earnings/26/02/50878945/canadian-imperial-bank-earnings-review-q1-summary",
            "pub_date": "2026-02-26 18:30:07",
            "source": "benzinga",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "69a020b024c37e0001bb2e76",
            "title": "Canadian Imperial Bank Q1 Earnings Assessment",
            "description": "<div><div class=\"sc-gfrmXj kPLDLR\"><!--$--><p class=\"block core-block\"><strong>Canadian Imperial Bank</strong> (NYSE:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/CM\" target=\"_blank\">CM</a>) just disclosed its Q1 earnings on Thursday, February 26, 2026 at 05:30 AM.</p><!--/$--><!--$--><p class=\"block core-block\">Here's a brief overview of the earnings report.</p><!--/$--><!--$--><h3 class=\"block core-block\">Earnings</h3><!--/$--><!--$--><p class=\"block core-block\">Canadian Imperial Bank beat estimated earnings by 13.79%, reporting an EPS of $1.98 versus an estimate of $1.74.</p><!--/$--><!--$--><p class=\"block core-block\">Revenue was up $897.00 million from the same period last year.</p><!--/$--><!--$--><h3 class=\"block core-block\">Analysis of Past Earnings</h3><!--/$--><!--$--><p class=\"block core-block\">Last quarter the company beat on EPS by $0.11 which was followed by a 0.64% increase in the share price the next day.</p><!--/$--><!--$--><p class=\"block core-block\">Here's a look at Canadian Imperial Bank's past performance:</p><!--/$--><!--$?--><template id=\"B:2\"></template><div></div><!--/$--><!--$--><p class=\"block core-block\">To track all earnings releases for Canadian Imperial Bank <a href=\"https://www.benzinga.com/quote/CM/earnings\" target=\"_blank\">visit their earnings calendar here.</a> </p><!--/$--><!--$--><p class=\"block core-block\">This article was generated by Benzinga's automated content engine and reviewed by an editor.</p><!--/$--></div></div>",
            "image": "https://www.benzinga.com/files/images/story/2025/11/06/analyst_ratings_2.jpg",
            "link": "https://www.benzinga.com/insights/earnings/26/02/50878946/canadian-imperial-bank-q1-earnings-assessment",
            "pub_date": "2026-02-26 18:30:12",
            "source": "benzinga",
            "kind": 1,
            "language": "en"
        }
    ]
}